The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...

A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi’s (SNY) said FDA lifted a hold on a trial to test over-the-counter use of its Eli-Lilly (LLY)-partnered erectile ...

SK bioscience and Sanofi have announced plans for global Phase III studies, which will assess the safety and immunogenicity ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

FORMER officials of the Department of Health (DOH) and Food and Drug Administration (FDA) were aware of the adverse effects ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Sanofi Pasteur, the global vaccines business unit of the French drug maker Sanofi, has joined forces with a US government department to develop a novel COVID-19 coronavirus vaccine.

Official Action Indicated (OAI). Not many investors may have heard of this. But they would surely have felt its impact. For, the moment OAI is triggered, the stock price slips sharply. OAI is nothing ...